BDTX - NASDAQ

Black Diamond Therapeutics, Inc.

BDTX·NASDAQ

$2.10

-7.1%

HealthcareBiotechnology

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$120.33M

EPS0.3900

P/E Ratio5.38

Earnings Date08/06/2026

143.01M

Assets

17%

3Y-8.0%

5Y-57.0%

10Y+1683.0%

30.80M

Total Liabilities

-22%

3Y-24.0%

5Y+41.0%

10Y+110.0%

112.21M

Total Equity

35%

3Y-3.0%

5Y-64.0%

10Y-1781.0%

Black Diamond Therapeutics, Inc. Funding & Solvency Profile

BDTX · NASDAQ

Current Assets

Cash & Cash Equivalents20.99M

Net Receivables0.00

Inventory0.00

Other Current Assets3.79M

Total Current Assets132 M

Non-Current Assets

Property, Plant & Equipment9.67M

Goodwill & Intangible Assets0.00

Long-Term Investments829.00K

Other Non-Current Assets73.00K

Total Non-Current Assets11 M

Total Assets

143.01M

Financial Health Analysis

Current Ratio

8.42x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.27x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

117 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

93% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Black Diamond Therapeutics, Inc. Balance Sheet

BDTX • NASDAQ

Black Diamond Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	21M	36.4M	56.2M	34.3M	65.8M	34.6M	154.7M	51.7M	7.9M
Short-Term Investments	107.7M	62.1M	75.2M	88.5M	144M	280.5M	0.0	0.0	0.0
Cash & Short-Term Investments	128.7M	98.6M	131.4M	122.8M	209.8M	315.1M	154.7M	51.7M	7.9M
Prepaids	0.0	0.0	0.0	0.0	5.9M	4.5M	1M	24K	36K
Other Current Assets	3.8M	2.6M	2.6M	4.9M	0.0	0.0	-1M	0.0	0.0
Total Current Assets	132.4M	101.2M	134M	127.7M	215.7M	319.6M	154.7M	51.7M	7.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	9.7M	20.4M	23.7M	27.4M	30.7M	8.8M	164K	134K	102K
Long-Term Investments	829K	0.0	0.0	0.0	0.0	0.0	55K	0.0	0.0
Other Non-Current Assets	73K	1.1M	823K	1.2M	1.2M	1.3M	3.4M	8K	5K
Total Non-Current Assets	10.6M	21.5M	24.5M	28.5M	32M	10.1M	3.6M	142K	107K
Total Assets	143M	122.6M	158.6M	156.3M	247.7M	329.7M	158.3M	51.8M	8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	579K	4M	2.3M	1.9M	4.1M	2.5M	2M	416K	152K
Accounts Payable	579K	4M	2.3M	1.9M	4.1M	2.5M	2M	416K	152K
Accrued Expenses	0.0	13.2M	14.2M	10.5M	19.2M	10.6M	2.9M	2.2M	2.1M
Capital Lease Obligations (Current)	0.0	3.4M	3.1M	2.8M	320K	1M	0.0	0.0	0.0
Other Current Liabilities	15.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	15.7M	20.6M	19.6M	15.3M	23.6M	14.2M	4.9M	2.6M	2.2M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	60.8M	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	200.6M	4M	12.5M
Total Non-Current Liabilities	15.1M	18.8M	22.2M	25.3M	28.1M	7.7M	200.6M	64.8M	12.5M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	3.8M	0.0	0.0
Capital Lease Obligations	15.1M	22.2M	25.3M	28.1M	28.5M	8.7M	0.0	0.0	0.0
Total Liabilities	30.8M	39.4M	41.8M	40.6M	51.8M	21.9M	209.3M	67.4M	14.7M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100K	56K
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	200.6M	60.8M	12.5M
Common Stock	8K	7K	7K	5K	5K	5K	1K	1K	1K
Additional Paid-In Capital	576.8M	570.4M	534.2M	452.5M	440.1M	425.4M	3.8M	169K	105K
Retained Earnings	-464.7M	-487.1M	-417.4M	-335M	-243.8M	-118.2M	-51M	-15.7M	-6.8M
Accumulated Other Comprehensive Income/Loss	101K	24K	-27K	-1.8M	-414K	614K	-112K	-100K	-56K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	-200.6M	-60.7M	-12.4M
Total Stockholders' Equity	112.2M	83.3M	116.7M	115.7M	195.9M	307.8M	-51M	-15.5M	-6.7M
Total Equity	112.2M	83.3M	116.7M	115.7M	195.9M	307.8M	-51M	-15.5M	-6.7M
SUMMARY
Total Liabilities & Equity	143M	122.6M	158.6M	156.3M	247.7M	329.7M	158.3M	51.8M	8M
Total Investments	108.5M	62.1M	75.2M	88.5M	144M	280.5M	55K	0.0	0.0
Total Debt	15.1M	22.2M	25.3M	28.1M	28.5M	8.7M	200.6M	60.8M	12.5M
Net Debt	-5.9M	-14.3M	-30.9M	-6.2M	-37.3M	-25.9M	45.9M	9.1M	4.6M
Shares Outstanding	56,935,279	56,935,279	56,935,279	56,935,279	56,935,279	56,935,279	56,935,279	56,935,279	56,935,279

SEC Filings

BDTX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	June 26, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 16, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 16, 2026	March 16, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 03, 2025	December 03, 2025	2025	View Filing
S-3 S-3 N/A	November 13, 2025	November 13, 2025		View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 95 filings

Related Guides

Blog Categories

Continue your BDTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.